Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1 G93A ) of ALS

摘要: The development of new therapeutic strategies to treat amyotrophic lateral sclerosis (ALS) is utmost importance. use cyclic nitroxides such as tempol may provide neuroprotection and improve lifespan. We investigated whether (50 mg/kg) presents potential in SOD1G93A transgenic mice. Tempol treatment began at the asymptomatic phase disease (10th week) was administered every other day until week 14, after which it twice a final stage disease. animals were sacrificed 14 (initial symptoms—ISS) end (ES) lumbar spinal cord dissected processed for following techniques: Nissl staining evaluate neuronal survival; immunohistochemistry astrogliosis microgliosis (ISS ES); qRT-PCR expression neurotrophic factors pro-inflammatory cytokines (ISS); transmission electron microscopy alpha-motoneurons (ES). Behavioral analyses considering survival animals, bodyweight loss, Rotarod motor performance test started on 10 performed 3 days end-stage results revealed that with promoted greater (23%) ISS compared untreated maintained ES. intense reactivity astrocytes microglia observed vehicle reduced cords treated tempol. In addition, groups showed proinflammatory (IL1β TNFα) three-fold decrease TGFβ1 group vehicle. Altogether, our indicate has beneficial effects, delaying onset by enhancing decreasing glial cell during ALS progression